Literature DB >> 18670773

Guidelines for radioiodine therapy of differentiated thyroid cancer.

M Luster1, S E Clarke, M Dietlein, M Lassmann, P Lind, W J G Oyen, J Tennvall, E Bombardieri.   

Abstract

INTRODUCTION: The purpose of the present guidelines on the radioiodine therapy (RAIT) of differentiated thyroid cancer (DTC) formulated by the European Association of Nuclear Medicine (EANM) Therapy Committee is to provide advice to nuclear medicine clinicians and other members of the DTC-treating community on how to ablate thyroid remnant or treat inoperable advanced DTC or both employing large 131-iodine ((131)I) activities. DISCUSSION: For this purpose, recommendations have been formulated based on recent literature and expert opinion regarding the rationale, indications and contraindications for these procedures, as well as the radioiodine activities and the administration and patient preparation techniques to be used. Recommendations also are provided on pre-RAIT history and examinations, patient counselling and precautions that should be associated with (131)I iodine ablation and treatment. Furthermore, potential side effects of radioiodine therapy and alternate or additional treatments to this modality are reviewed. Appendices furnish information on dosimetry and post-therapy scintigraphy.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18670773     DOI： 10.1007/s00259-008-0883-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


  120 in total

1.  Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy.

Authors:  K H Dow; B R Ferrell; C Anello
Journal:  Thyroid       Date:  1997-08       Impact factor: 6.568

2.  Thyroid stunning in vivo and in vitro.

Authors:  Mario Medvedec
Journal:  Nucl Med Commun       Date:  2005-08       Impact factor: 1.690

3.  Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration.

Authors:  Markus Luster; Ralph Felbinger; Markus Dietlein; Christoph Reiners
Journal:  Thyroid       Date:  2005-10       Impact factor: 6.568

4.  Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.

Authors:  Heribert Hänscheid; Michael Lassmann; Markus Luster; Stephen R Thomas; Furio Pacini; Claudia Ceccarelli; Paul W Ladenson; Richard L Wahl; Martin Schlumberger; Marcel Ricard; Al Driedger; Richard T Kloos; Steven I Sherman; Bryan R Haugen; Vincent Carriere; Carine Corone; Christoph Reiners
Journal:  J Nucl Med       Date:  2006-04       Impact factor: 10.057

5.  Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen.

Authors:  I Borget; H Remy; J Chevalier; M Ricard; M Allyn; M Schlumberger; G De Pouvourville
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-02       Impact factor: 9.236

6.  Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer.

Authors:  H R Maxon; S R Thomas; V S Hertzberg; J G Kereiakes; I W Chen; M I Sperling; E L Saenger
Journal:  N Engl J Med       Date:  1983-10-20       Impact factor: 91.245

7.  Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma.

Authors:  K Tharp; O Israel; J Hausmann; L Bettman; W H Martin; M Daitzchman; M P Sandler; D Delbeke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-19       Impact factor: 9.236

8.  Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine.

Authors:  F Pacini; F Cetani; P Miccoli; F Mancusi; C Ceccarelli; F Lippi; E Martino; A Pinchera
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

9.  124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact.

Authors:  L S Freudenberg; W Jentzen; R Görges; T Petrich; R J Marlowe; J Knust; A Bockisch
Journal:  Nuklearmedizin       Date:  2007       Impact factor: 1.379

10.  A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer.

Authors:  Tania Pilli; Ernesto Brianzoni; Francesca Capoccetti; Maria Grazia Castagna; Sara Fattori; Angela Poggiu; Gloria Rossi; Francesca Ferretti; Elisa Guarino; Luca Burroni; Angelo Vattimo; Claudia Cipri; Furio Pacini
Journal:  J Clin Endocrinol Metab       Date:  2007-07-03       Impact factor: 5.958
View more
  142 in total

Review 1.  ALARA in rhTSH-stimulated post-surgical thyroid remnant ablation: what is the lowest reasonably achievable activity?

Authors:  Daniele Barbaro; Frederik A Verburg; Markus Luster; Christoph Reiners; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-20       Impact factor: 9.236

2.  Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer.

Authors:  Frederik A Verburg; Cumali Aktolun; Arturo Chiti; Savvas Frangos; Luca Giovanella; Martha Hoffmann; Ioannis Iakovou; Jasna Mihailovic; Bernd J Krause; Werner Langsteger; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-17       Impact factor: 9.236

Review 3.  2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer.

Authors:  Laura Fugazzola; Rossella Elisei; Dagmar Fuhrer; Barbara Jarzab; Sophie Leboulleux; Kate Newbold; Jan Smit
Journal:  Eur Thyroid J       Date:  2019-08-28

Review 4.  Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma.

Authors:  Frederik A Verburg; Markus Dietlein; Michael Lassmann; Markus Luster; Christoph Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

5.  Comment on: Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective.

Authors:  Markus Luster; Martin Schlumberger; Furio Pacini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-18       Impact factor: 9.236

6.  Diet and 18F bone imaging.

Authors:  V Ralph McCready; Sabina Dizdarevic
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-27       Impact factor: 9.236

Review 7.  Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita
Journal:  Thyroid       Date:  2015-07       Impact factor: 6.568

8.  Clinical Usefulness of F-18 FDG PET/CT in Papillary Thyroid Cancer with Negative Radioiodine Scan and Elevated Thyroglobulin Level or Positive Anti-thyroglobulin Antibody.

Authors:  Su Jung Choi; Kyung Pyo Jung; Sun Seong Lee; Yun Soo Park; Seok Mo Lee; Sang Kyun Bae
Journal:  Nucl Med Mol Imaging       Date:  2015-10-22

Review 9.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

10.  Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality.

Authors:  Alexis Vrachimis; Burkhard Riemann; Uwe Mäder; Christoph Reiners; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-23       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.